March 14, 2007 – Critical Therapeutics and a division of German Merck will co-promote respiratory drugs; Curis selected its first anti-cancer compound for development; Avigen can begin a Phase II test of a drug for spasticity and muscle spasms; the FDA accepted the filing by Adams Respiratory for approval of an extended-release cough surpressant; Advanced Life Sciences received Orphan Drug Designation for an anthrax drug; Memory began dosing patients in a Phase IIa trial of its Alzheimer’s disease compound; and Roche ended a collaboration with Maxygen. The Centient Biotech 200™ rose 22 points to end at 3805, an increase of .58%. More details...
